GSK partners with Rgenta on RNA-targeted small molecules for oncology, other...
GSK will team up with Boston-area biotech Rgenta Therapeutics to create oral small molecules that target RNA, the companies said Wednesday morning. The duo will discover and develop splice modulators...
View ArticleUpdated: CEO of UnitedHealth insurance unit shot and killed in New York in...
UnitedHealthcare CEO Brian Thompson was shot and killed in Midtown Manhattan Wednesday morning ahead of the insurer's investor day, according to the company and police. The New York Police Department...
View ArticleGeneDx bets that rare disease data can aid drug discovery
Two years ago, GeneDx was teetering. The genetic testing company had laid off 33% of its staff, shares were down 90% from a year prior, and some investors were skeptical of a turnaround plan. ...
View ArticleRelmada's rapid-acting NMDA depression drug expected to fail second Phase 3
Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. The study’s data monitoring committee said...
View ArticleAstraZeneca's new EVP of international amid China investigation; Janux’s...
Plus, news about Arrakis, Eli Lilly, Everest Medicines, Teva, Rondo Therapeutics, Trevi Therapeutics, Foresee Pharmaceuticals and Revolution Medicines: AstraZeneca taps new leader to run China...
View ArticleNovavax sells Czech facility to Novo Nordisk for $200M to cut costs
Novo Nordisk is buying a vaccine manufacturing factory from Novavax for $200 million to expand production of its current and future mammalian-based products, a spokesperson for the Danish drugmaker...
View ArticleSickle cell gene therapies included in new Medicaid access model
The Biden Administration said Wednesday that it has secured agreements with Vertex Pharmaceuticals and bluebird bio for their sickle cell disease gene therapies to be the first in a new access model...
View ArticleTrade group tells FDA that semaglutide is not too 'complex' for compounding
The Alliance for Pharmacy Compounding told the FDA last week that Novo Nordisk's weight loss medicine semaglutide is not too difficult to compound, pushing back against the Danish pharma's arguments...
View ArticleModerna defends pandemic prep as vaccine skeptics gain power
Moderna CEO Stéphane Bancel argued that the drug industry's efforts to prepare for a future pandemic are meant to protect Americans, defending the sector's work even as President-elect Donald Trump...
View ArticleNovo Nordisk budgets $409M for new quality control lab in Denmark
Novo Nordisk is spending DKK 2.9 billion ($409 million) to build a new quality control laboratory and will move existing operations into the site to create a “central hub.” The new 53,000-square meter...
View ArticleGSK, Zhifei extend shingles vaccine pact for less money
In a week of back-to-back new deals, GSK is extending its Shingrix agreement in China and adding a collaboration for its RSV vaccine Arexvy. But the changes mean the UK pharma could get millions of ...
View ArticleCG Oncology’s bladder cancer treatment shows durability potential in Phase 3
CG Oncology says its immunotherapy candidate that could help patients avoid surgery may deliver lasting responses in a certain form of bladder cancer based on late-stage trial data. The California...
View ArticleNuvig raises $161M as it prepares for Phase 2 study in hot autoimmune field
An immunomodulatory startup called Nuvig Therapeutics announced a $161 million Series B amid rising competition to develop new and better autoimmune medicines. Nuvig, based in Menlo Park, CA, is...
View ArticleGSK's third new pact of the week focuses on Alzheimer's with startup Muna...
GSK's BD team was busy leading up to the Thanksgiving holiday. In the last two days, the UK-based pharma has announced three new partnerships on top of
View ArticleUK to limit access to Lilly’s Zepbound; VivaVision’s positive Phase 2
Plus, news about Atlas Venture: NICE plans a limited rollout of Eli Lilly’s Zepbound: The UK’s drug price watchdog confirmed its prior recommendation for the weight loss drug, but it plans to ...
View ArticleGenmab licenses second monoclonal antibody from Scancell
Genmab is licensing a second investigational anti-glycan monoclonal antibody from Scancell as part of an agreement inked between the two companies in 2022. Scancell, a British immunotherapy biotech,...
View ArticleNational Resilience's new CEO; Moderna opens Australian manufacturing site
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. National Resilience is replacing its CEO effective immediately with...
View ArticleMerck’s Eliav Barr on its LaNova deal and the unknowns of VEGF bispecifics
Merck’s top medical exec said its recent bet on a VEGF bispecific antibody — one of the hottest areas in R&D — is not a form of “insurance” against future competition for Keytruda. The pharma...
View ArticleProtara’s stock nearly doubles as biotech divulges new bladder cancer data
Protara Therapeutics reported that 13 of 18 bladder cancer patients who received its experimental cell therapy saw no signs of their cancer at six months. Two of three patients who received ...
View ArticleAmgen deepens roots in North Carolina with latest $1B factory build
Amgen is investing $1 billion for a second factory in North Carolina after already allocating more than half a billion dollars for a separate facility in the state. The latest factory in Holly Springs...
View Article